Provectus Biopharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-13.5M | $-24.4M | $-24.5M | $-10.2M | $-27.7M | $-12.6M | $-19.4M | $-18.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $15.9K | $13.1K | $13.2K | $8.5K | $6.4K | $6.2K | $7.4K | $8.9K |
| Amortization | $671.1K | $671.1K | $671.1K | $671.1K | $671.1K | $671.1K | $671.1K | $671.1K |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-10.3M | $-21.9M | $-17.4M | $-13.8M | $-9.9M | $-11.3M | $-17.2M | $-13.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $30.4K | — | $6.1K | $70.6K | $6.7K | $15.9K | $6.1K | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-30.4K | — | — | $-70.6K | $-6.7K | $-15.9K | $-6.1K | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | $0 | — |
| Net Cash from Financing Activities | $9.3M | — | — | — | $24.4M | $4.8M | $16.8M | $18.6M |
| Net Change in Cash | $-1.1M | $-13.0M | $-3.2M | $1.7M | $14.5M | $-6.5M | $-380.4K | $4.8M |
| Free Cash Flow | $-10.4M | — | $-17.4M | $-13.9M | $-9.9M | $-11.3M | $-17.2M | — |